

Deficiency of the Complement Component 3 but Not Factor B Aggravates *Staphylococcus aureus* Septic Arthritis in Mice

Manli Na,^a Anders Jarneborn,^{a,c} Abukar Ali,^a Amanda Welin,^a Malin Magnusson,^a Anna Stokowska,^b Marcela Pekna,^b  Tao Jin^{a,c}

Department of Rheumatology and Inflammation Research, Institution of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden^a; Center for Brain Repair and Rehabilitation, Department of Clinical Neuroscience and Rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden^b; Department of Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden^c

The complement system plays an essential role in the innate immune response and protection against bacterial infections. However, detailed knowledge regarding the role of complement in *Staphylococcus aureus* septic arthritis is still largely missing. In this study, we elucidated the roles of selected complement proteins in *S. aureus* septic arthritis. Mice lacking the complement component 3 ($C3^{-/-}$), complement factor B ($fB^{-/-}$), and receptor for C3-derived anaphylatoxin C3a ($C3aR^{-/-}$) and wild-type (WT) control mice were intravenously or intra-articularly inoculated with *S. aureus* strain Newman. The clinical course of septic arthritis, as well as histopathological and radiological changes in joints, was assessed. After intravenous inoculation, arthritis severity and frequency were significantly higher in $C3^{-/-}$ mice than in WT controls, whereas $fB^{-/-}$ mice displayed intermediate arthritis severity and frequency. This was in accordance with both histopathological and radiological findings. C3, but not fB, deficiency was associated with greater weight loss, more frequent kidney abscesses, and higher bacterial burden in kidneys. *S. aureus* opsonized with $C3^{-/-}$ sera displayed decreased uptake by mouse peritoneal macrophages compared with bacteria opsonized with WT or $fB^{-/-}$ sera. C3aR deficiency had no effect on the course of hematogenous *S. aureus* septic arthritis. We conclude that C3 deficiency increases susceptibility to hematogenous *S. aureus* septic arthritis and impairs host bacterial clearance, conceivably due to diminished opsonization and phagocytosis of *S. aureus*.

Septic arthritis is considered one of the most dangerous joint diseases owing to its rapidly progressive disease character, relatively high mortality, and poor prognosis. *Staphylococcus aureus* is the most common cause of bacterial arthritis (1, 2). The risk factors for acquiring septic arthritis include increasing age, preexisting joint diseases, and decreased immunocompetence (1). An additional challenge is posed by increasing antibiotic resistance of *S. aureus* and the spread of highly virulent methicillin-resistant strains in past decades (3).

Nonspecific innate immune responses, including neutrophils (4) and NK cells (5), are generally considered to be protective against septic arthritis, whereas certain cell types, e.g., CD4⁺ T cells of the acquired immune system, potentiate the severity of disease by triggering exaggerated responses (6, 7). The complement system, one of the essential components of the innate immune response, not only participates in recognizing and eliminating invading microorganisms (8), but also enhances the adaptive immune responses (9). Activation of complement by *S. aureus* can be mediated through all three different pathways, classical, lectin, and alternative, all of which share the common step of activating the central component, complement component 3 (C3), which generates bacterium-bound opsonin, C3b; anaphylatoxins C3a and C5a; and the formation of the lytic membrane attack complex (MAC). Gram-positive bacteria are generally protected from MAC (C5b-9)-mediated lysis by their thick peptidoglycan layer (10). However, the very distinct location of C5b-9 deposits on their cell surfaces, which contrasts with the random deposition of C3b, suggests some yet-to-be-determined function of C5b-9 (11). The role of the complement system was intensively studied in a mouse model of *S. aureus* sepsis. It has been shown that C3 is more critical than C4 and C5 in controlling *S. aureus* bacteremia. Also, complement receptor 1 and 2 deficiency led to increased mortality in mice with *S. aureus* bacteremia (12, 13). Compared to C3, man-

nose-binding lectin deficiency had a smaller but significant effect on survival of *S. aureus* sepsis, and this effect was not C3 dependent (14, 15). So far, however, very little is known about the specific role of the complement system in the pathogenesis of septic arthritis. The only study was done by Sakiniene et al. using cobra venom factor to induce an enormous activation of the complement system, resulting in complement depletion. Complement depletion by this strategy significantly aggravated *S. aureus* septic arthritis in mice (16). However, this strategy does not allow the elucidation of the exact roles of different complement proteins in *S. aureus* septic arthritis.

In the present study, we compared the susceptibilities to *S. aureus* septic arthritis of mice lacking C3, complement factor B (fB), and receptor for C3-derived anaphylatoxin C3a (C3aR) using our well-established murine models for *S. aureus* arthritis. Our data demonstrate that C3 deficiency greatly increased susceptibility to staphylococcal hematogenous septic arthritis. In contrast, neither C3aR nor fB deficiency had a significant effect on the development of septic arthritis.

Received 15 December 2015 Returned for modification 28 December 2015
Accepted 11 January 2016

Accepted manuscript posted online 19 January 2016

Citation Na M, Jarneborn A, Ali A, Welin A, Magnusson M, Stokowska A, Pekna M, Jin T. 2016. Deficiency of the complement component 3 but not factor B aggravates *Staphylococcus aureus* septic arthritis in mice. *Infect Immun* 84:930–939. doi:10.1128/IAI.01520-15.

Editor: L. Pirofski

Address correspondence to Tao Jin, tao.jin@rheuma.gu.se.

Copyright © 2016 Na et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

MATERIALS AND METHODS

Mice. $C3^{-/-}$ (17), $C3aR^{-/-}$ (18), and $fB^{-/-}$ (19) mice were backcrossed to the C57BL/6 genetic background for 10 generations. The mice were kept under standard conditions of temperature and light and were fed laboratory chow and water *ad libitum*. Mice of both sexes were used for experiments at the age of 6 to 10 weeks. For each experiment, the ages and sexes of the mice were matched. The ethics committee of animal research of Gothenburg approved the study.

Bacterial strain and reagents. *S. aureus* strain Newman was cultured on blood agar plates for 24 h, harvested, and kept frozen at -20°C in phosphate-buffered saline (PBS) containing 5% bovine serum albumin (BSA) and 10% dimethyl sulfoxide (DMSO). Before experiments, the bacterial suspension was thawed, washed in PBS, and adjusted to the required concentration (20).

Mouse model for hematogenous *S. aureus* arthritis. We used a well-established mouse model of septic arthritis closely resembling the human infectious arthritis that is hematogenously spread (21). Mice were inoculated intravenously (i.v.) in the tail vein with 0.2 ml of staphylococcal suspension and euthanized on day 10 postinoculation (22).

First, we sought to find the optimal arthritogenic dose for $C3^{-/-}$ mice. Different doses (1×10^5 to 1×10^7 CFU/mouse) of *S. aureus* Newman were used. As a dose of 4×10^6 CFU/mouse induced septic arthritis in around 65% of $C3^{-/-}$ animals, this dose was chosen for all other experiments. To study the roles of C3, C3aR, and factor B in hematogenous staphylococcal arthritis, all the mice ($C3^{-/-}$, $fB^{-/-}$, $C3aR^{-/-}$, and wild type [WT]; $n = 10$ to 29) were intravenously inoculated with 4×10^6 CFU of *S. aureus* Newman. The mice were regularly weighed and examined for arthritis by observers blinded to the groups (T.J. and A.A.). On day 10, the mice were killed, kidneys were obtained for assessment of kidney abscesses and bacterial persistence, serum samples were collected to assess cytokine levels, and paws were obtained for radiological examination of bone erosions followed by microscopic evaluation of synovitis and destruction of cartilage and bone.

To study whether opsonization of *S. aureus* in WT serum prior to inoculation would affect the clinical course of hematogenous septic arthritis in $C3^{-/-}$ mice, *S. aureus* Newman bacteria were incubated with 25% sera from WT and $C3^{-/-}$ mice in PBS at 37°C for 30 min. Incubation with mouse sera did not influence the bacterial viable counts (data not shown). The bacteria were then diluted to the expected concentration and injected i.v. into $C3^{-/-}$ mice ($n = 10$ /group). The mice were regularly followed by observers blinded to the treatment groups (T.J. and A.A.) for 10 days, and kidneys were obtained for assessment of kidney abscesses.

Clinical evaluation of arthritis. Observers blinded to the treatment groups visually inspected all 4 limbs of each mouse (23). Arthritis was defined as erythema and/or swelling of the joints. To evaluate the severity of arthritis, a clinical scoring system ranging from 0 to 3 was used for each paw (0, no inflammation; 1, mild visible swelling and/or erythema; 2, moderate swelling and/or erythema; 3, marked swelling and/or erythema). The arthritis index was constructed by adding the scores from all 4 limbs for each animal as described previously (23, 24). Arthritis that involved 2 or more joints simultaneously was defined as polyarthritis. Since the signs of septic arthritis in deeper joints (e.g., the knee and elbow joints) are impossible to evaluate clinically, micro-computed tomography (μCT) and histopathological examination of joints were further used to confirm the clinical arthritis data.

Bacteriological examination. Kidneys were aseptically removed and blindly assessed by one investigator (T.J.) for abscesses. A scoring system ranging from 0 to 3 was used (0, healthy kidneys; 1, 1 or 2 small abscesses on kidneys without structural changes; 2, more than 2 abscesses but <75% of kidney tissue involved; and 3, large amounts of abscesses with >75% of kidney tissue involved) (22). Afterward, the kidneys were homogenized, diluted serially in PBS, and transferred to agar plates containing 5% horse blood. Bacteria were grown for 24 h and quantified as CFU.

μCT . Joints were fixed in 4% formaldehyde for 3 days and then transferred to PBS for 24 h. Afterward, all 4 limbs were scanned and recon-

structed into a three-dimensional (3D) structure with a Skyscan1176 micro-CT (Bruker, Antwerp, Belgium) with a voxel size of 35 μm . The scanning was done at 55 kV and 455 mA, with a 0.2-mm aluminum filter. The exposure time was 47 ms. The X-ray projections were obtained at 0.7° intervals with a scanning angular rotation of 180° . The projection images were reconstructed into three-dimensional images using NRECON software (version 1.5.1; Bruker). After reconstruction, the 3D structures of each joint were blindly assessed by 2 observers (T.J. and M.M.) using a scoring system from 0 to 3 (0, healthy joint; 1, mild bone destruction; 2, moderate bone destruction; 3, marked bone destruction) (22, 23, 25).

Mouse model for local *S. aureus* arthritis. $C3^{-/-}$, $fB^{-/-}$, and WT mice ($n = 10$ to 14) were inoculated in the knee joints with 1×10^5 CFU of *S. aureus* Newman bacteria/joint in a total volume of 20 μl PBS. Viable-cell counts were performed to determine the number of bacteria injected. The mice were killed 7 days later. Knee joints were collected for μCT scan and histological examination.

Histopathological examination of joints. After the scanning, the joints were decalcified, embedded in paraffin, and sectioned with a microtome. Tissue sections were stained with hematoxylin and eosin. All the slides were coded and assessed in a blinded manner by two observers (M.M. and M.N.) with regard to the degree of synovitis and cartilage/bone destruction. The extent of synovitis and cartilage/bone destruction was judged as previously described (22, 24).

Peritoneal macrophage phagocytosis assay. An imaging flow-cytometry-based method was employed to analyze the phagocytic capacity of peritoneal macrophages, as previously described (26). Briefly, green fluorescent protein (GFP)-expressing *S. aureus* (multiplicity of infection [MOI], 5) bacteria were incubated with 25% sera from WT, $C3^{-/-}$, and $fB^{-/-}$ mice in PBS at 37°C for 30 min. Peritoneal leukocytes from 5 WT mice were collected using peritoneal lavage with 10 ml ice-cold PBS. The mixed peritoneal cells were incubated with opsonized GFP-expressing *S. aureus* bacteria at 37°C for 1 h. The cells were then placed on ice, and macrophages were stained with allophycocyanin (APC)-eFluor780-conjugated rat anti-mouse F4/80 antibody (eBioscience), followed by immediate analysis on an imaging flow cytometer (ImageStreamX MkII and IDEAS software v.6.0; Merck Millipore, Germany). The internalization wizard in IDEAS was used to determine whether the GFP-positive bacteria had internalized or merely bound the phagocytes. Data are presented as the percentage of macrophages with internalized *S. aureus*.

Measurement of cytokine levels. The cytokine levels in serum were determined using a Cytometric Bead Array (CBA) mouse inflammation cytokine kit (BD Biosciences) and analyzed using a FACS Canto2 flow cytometer (BD Biosciences). The data were analyzed using FCAP array software (BD Biosciences). The levels of monocyte chemoattractant protein 1 (MCP-1), chemokine (C-C motif) ligand 5 (CCL-5), and receptor activator of nuclear factor kappa B ligand (RANKL) in serum were quantified using DuoSet ELISA Development System kits (R&D Systems, Abingdon, United Kingdom) according to the manufacturer's protocols.

Statistical analysis. Statistical significance was assessed using the Kruskal-Wallis test, *post hoc* Dunn's multiple-comparison test, or Mann-Whitney test for continuous variables and the chi-square test or Fisher's exact test for categorical variables. The results are reported as the mean and the standard error of the mean (SEM) unless otherwise stated. *P* values of <0.05 were considered statistically significant.

RESULTS

C3 deficiency increases the severity and frequency of hematogenous septic arthritis. In the first experiment, only $C3^{-/-}$ and WT mice ($n = 10$ /group) were used. $C3^{-/-}$ mice developed significantly more severe and frequent clinical arthritis than WT mice (data not shown).

Next, to elucidate the contributions of alternative pathways to the above-mentioned findings, $C3^{-/-}$, $fB^{-/-}$, and WT mice were simultaneously infected i.v. with *S. aureus* in the second experiment. Compared to WT mice, $C3^{-/-}$ mice developed significantly




FIG 1 Effects of C3 and fB deficiency on the course of hematogenous staphylococcal arthritis. *C3^{-/-}*, *fB^{-/-}*, and WT mice were intravenously inoculated with *S. aureus* strain Newman (4×10^6 CFU/mouse) and sacrificed on day 10. (A and B) The severity (A) and frequency (B) of clinical arthritis were observed for 10 days postinfection. (C) Histological evaluation of the joints from all 4 limbs 10 days after infection. (D) (Top) Micrograph of histologically intact knee joints from a WT mouse inoculated with *S. aureus* strain Newman. (B) Micrograph of a heavily inflamed knee joint with severe bone and cartilage destruction from a *C3^{-/-}* mouse with septic arthritis (hematoxylin and eosin staining). Original magnification, $\times 10$. The asterisk indicates heavily inflamed synovium. B, bone; C, cartilage; E, erosion of bone and cartilage; JC, joint cavity; S, synovial tissue. (E and F) Frequency of bone destruction (E) and cumulative bone destruction scores (F) of the joints from all 4 limbs of WT, *C3^{-/-}*, and *fB^{-/-}* mice as assessed by micro-computed tomography scan. (G) (Left) Intact wrist from a WT mouse inoculated with *S. aureus*. (Right) Heavily destroyed wrist (both distal radius and ulna) joints from a *C3^{-/-}* mouse with septic arthritis. The arrow indicates bone destruction. The values shown are means and SEM. ***, $P < 0.001$; **, $P < 0.01$; *, $P < 0.05$; n.s, not significant (Kruskal-Wallis test followed by Dunn's multiple-comparison test or chi-square test).

more severe clinical arthritis as early as day 5, and with time, the difference increased and stabilized until the end of the experiment, whereas *fB^{-/-}* mice had more severe clinical arthritis only on day 1 (Fig. 1A).

The frequency of arthritis was higher in the *C3^{-/-}* mice than in the WT mice (Fig. 1B). Already on day 1, 47% of *C3^{-/-}* mice had developed arthritis versus 12% of WT mice ($P < 0.05$), and at the end of the experiment, the difference was even more pronounced

(74% versus 7%; $P < 0.001$) (Fig. 1B). *fB^{-/-}* mice showed an intermediate arthritis frequency (44% on day 10).

Since the arthritis of deeper joints was impossible to assess by clinical evaluation, histopathological examination of all joints was used. In line with clinical arthritis data, histopathologically verified synovitis and the extent of joint destruction were significantly enhanced in *C3^{-/-}* mice compared with WT controls and *fB^{-/-}* mice (Fig. 1C). A joint with septic arthritis on day 10 after infection is

TABLE 1 Subgroup analysis of bone destruction in different joint groups by μ CT scan^a

Joint group	Severity (mean \pm SEM)			Frequency (%)		
	WT	$C3^{-/-}$	$fB^{-/-}$	WT	$C3^{-/-}$	$fB^{-/-}$
Front paws	0.77 \pm 0.31	1.78 \pm 0.37	0.56 \pm 0.22	30	58 ^{b,c}	28
Elbows	0	0	0	0	0	0
Shoulders	0.20 \pm 0.14	1.03 \pm 0.20 ^{c,d}	0.25 \pm 0.14	13	58 ^{c,d}	22
Hips	0.03 \pm 0.03	0.57 \pm 0.21 ^{b,c}	0	3	26 ^{b,c}	0
Knees	0.17 \pm 0.09	0.54 \pm 0.15 ^c	0.06 \pm 0.06	10	37 ^{b,c}	6
Hind paws	0.88 \pm 0.26	1.51 \pm 0.33	0.33 \pm 0.17	37	47 ^c	17

^a Statistical evaluations were performed using the Kruskal-Wallis test and Fisher's exact test.

^b $P < 0.05$ ($C3^{-/-}$ versus WT).

^c $P < 0.05$ ($C3^{-/-}$ versus $fB^{-/-}$).

^d $P < 0.001$ ($C3^{-/-}$ versus WT).

typically identified by heavily inflamed synovium and severe cartilage and bone erosions (Fig. 1D, bottom), whereas a healthy joint is characterized by a single-layer synovium without inflammatory infiltration and intact cartilage (Fig. 1D, top). The $fB^{-/-}$ and WT mice showed comparable extents of arthritis at the histopathological level.

Importantly, the data from μ CT, a state of the art technique for the assessment of joint changes, confirmed the results from histopathological examination. $C3^{-/-}$ mice had significantly more joints with bone erosion on the μ CT scan than WT ($P < 0.0001$) and $fB^{-/-}$ ($P < 0.01$) mice, whereas no difference was observed between $fB^{-/-}$ and WT mice (Fig. 1E). A similar pattern was observed with regard to the severity of bone erosion (Fig. 1F).

Next, we performed a more detailed subgroup analysis to investigate which specific joints were affected by *S. aureus* infection (Table 1). The extent of bone destruction was significantly higher in the shoulders and hips of the $C3^{-/-}$ mice than in those of the WT and $fB^{-/-}$ mice. Also, $C3^{-/-}$ mice exhibited a significantly higher frequency of bone erosions in the front paws, shoulders, hips, knees, and hind paws than both WT and $fB^{-/-}$ mice. Strikingly, no bone erosion was found in elbow joints from any group, suggesting that C3 deficiency facilitates bacterial invasion of the majority of joints, but not the elbow joints.

C3, but not fB, deficiency led to greater body weight loss and impaired bacterial clearance. Negative body weight development

was observed in $C3^{-/-}$ mice during the whole course of disease compared with WT mice, whereas $fB^{-/-}$ mice had significantly more weight loss than WT mice only on day 1 (Fig. 2A). WT mice lost around 4% of their total body weight by day 3 but started to regain weight thereafter and reached around 99% of their initial body weight by day 10. In contrast, the weight curve of $C3^{-/-}$ mice continuously declined to 89% of the initial body weight ($P < 0.001$) on day 7 and slowly recovered to 93% of the initial body weight on day 10 ($P < 0.05$), suggesting more severe infection in $C3^{-/-}$ mice.

Macroscopically, more abscesses were observed in the kidneys in $C3^{-/-}$ mice than in both WT ($P < 0.05$) and $fB^{-/-}$ ($P < 0.01$) mice (Fig. 2B). Good correlation was found between the abscess score and the actual bacterial load in the kidneys ($r = 0.83$; $P < 0.0001$). In line with these results, the $C3^{-/-}$ mice had around 3,600-fold higher bacterial load in the kidneys than WT controls ($P < 0.01$) and $fB^{-/-}$ mice ($P < 0.01$) (Fig. 2C). This strongly suggests that C3 deficiency impairs the bacterial clearance capacity of the host. In contrast, no differences in the kidney abscess index and kidney bacterial load were found between $fB^{-/-}$ and WT mice.

C3 and fB deficiencies alter serum cytokine profiles in mice with hematogenous *S. aureus* septic arthritis. To investigate the systemic inflammatory response, we measured the levels in serum




FIG 2 C3 deficiency led to more pronounced body weight loss, more severe kidney abscesses, and higher *S. aureus* loads in kidneys. WT, $C3^{-/-}$, and $fB^{-/-}$ mice were intravenously inoculated with *S. aureus* strain Newman (4×10^6 CFU/mouse), and the animals were sacrificed on day 10. (A) Changes in body weight registered as percentages of the initial body weight. (B and C) Kidney abscess scores (B) and persistence of *S. aureus* in kidneys 10 days after infection (C). Shown are means and SEM for kidney abscesses and medians with interquartile ranges for the bacterial load in kidneys. ***, $P < 0.001$; **, $P < 0.01$; *, $P < 0.05$; n.s., not significant (Kruskal-Wallis test with Dunn's multiple-comparison test).




FIG 3 Serum cytokine profiles were altered in C3-deficient and fB-deficient mice inoculated with *S. aureus*. Levels of five inflammatory cytokines (IFN- γ , TNF- α , IL-6, IL-10, and IL-12), two chemokines (MCP-1 and CCL5), and RANKL in serum were determined after termination of the experiment on day 10 after infection. Shown are means and SEM. ***, $P < 0.001$; **, $P < 0.01$; *, $P < 0.05$; n.s., not significant (Kruskal-Wallis test with *post hoc* Dunn's multiple-comparison test).

of five cytokines (gamma interferon [IFN- γ], tumor necrosis factor alpha [TNF- α], interleukin 6 [IL-6], IL-10, and IL-12), two chemokines (MCP-1 and CCL5), and RANKL (Fig. 3A to G). Significantly lower levels of MCP-1 ($P < 0.001$) (Fig. 3A), CCL5 ($P < 0.01$) (Fig. 3B), IL-10 ($P < 0.05$) (Fig. 3C), and IL-12 ($P < 0.05$) (Fig. 3G) were found in the sera of C3^{-/-} mice than in those of WT mice. In contrast, TNF- α ($P < 0.05$) (Fig. 3E) and MCP-1 ($P < 0.001$) (Fig. 3A) levels were lower in fB^{-/-} than in WT mice. Intriguingly, significantly higher levels of IL-6 ($P < 0.05$) (Fig. 3F) but lower levels of CCL5 ($P < 0.05$) (Fig. 3B) and RANKL ($P < 0.05$) (Fig. 3H) were found in C3^{-/-} than in fB^{-/-} mice.

Peritoneal macrophages displayed impaired phagocytic capacity for *S. aureus* opsonized with C3^{-/-} sera. C3b acts as an opsonin that enhances the phagocytic capacity of cells, including neutrophils and macrophages, for bacteria. Image streaming, a state of the art technology, was applied to study the roles of C3 and fB in the phagocytic capacity of macrophages (Fig. 4). Bacterial numbers were similar after 30 min of incubation with C3^{-/-}, fB^{-/-}, and WT sera. Also, the phagocytic capacity of peritoneal macrophages from C3^{-/-} mice was intact when *S. aureus* was opsonized with sera from WT mice (data not shown). However, the percentage of macrophages with internalized *S. aureus* opsonized with C3^{-/-} sera was comparable to the internalization frequency of nonopsonized *S. aureus* (18% versus 21% [not significant]). Importantly, the internalization frequency was significantly increased when *S. aureus* was opsonized with sera from WT mice (41%; $P < 0.01$) or sera from fB^{-/-} mice (36%; $P < 0.05$), suggesting the crucial role of C3, but not fB, in the phagocytic capacity of macrophages for *S. aureus*.

Next, we asked whether opsonization of *S. aureus* in WT serum

prior to inoculation would affect the clinical course of arthritis after hematogenous inoculation in C3^{-/-} mice. Bacteria were incubated with C3^{-/-} or WT serum for 30 min, washed, and injected into C3^{-/-} mice. We observed a trend toward lower clinical arthritis scores and reduced arthritis frequency in mice inoculated with *S. aureus* that was preincubated with WT serum (Fig. 4C to F). Taken together, these results show that C3-mediated opsonization of *S. aureus* is critical for host defense against *S. aureus* hematogenous septic arthritis.

C3aR deficiency had no effect on the course of hematogenous septic arthritis. C3a exerts its proinflammatory functions by activating C3aR, whereas C3b functions as an opsonin (27). To elucidate whether the C3a/C3aR interaction plays a role in *S. aureus* septic arthritis, C3aR^{-/-} and WT mice were i.v. inoculated with *S. aureus* Newman and the course of septic arthritis was followed for 10 days (Fig. 5). No differences were found regarding the severity or frequency of arthritis (Fig. 5A and B). Also, the kidney abscess scores were similar in the two groups (Fig. 5D), although the C3aR^{-/-} mice lost more body weight than the WT controls. These results suggest that absence of C3a/C3aR signaling does not contribute to increased susceptibility of C3^{-/-} mice to hematogenous septic arthritis.

Neither C3 nor fB deficiency affects local *S. aureus* arthritis. To study the roles of C3 and fB in the late stage of septic arthritis, we injected *S. aureus* into the knee joints of NMRI (The Naval Medical Research Institute) mice to bypass the early immune responses in the bloodstream. Both synovitis severities and grades of bone erosion were similar among the three groups, which was also confirmed by the μ CT scan data (data not shown).




FIG 4 Peritoneal macrophages showed reduced phagocytic capacity for *S. aureus* opsonized with sera from $C3^{-/-}$ mice. Peritoneal leukocytes obtained by peritoneal lavage from five wild-type mice were incubated with GFP-expressing *S. aureus* (MOI, 5) that was opsonized with sera from WT, $C3^{-/-}$, and $fbB^{-/-}$ mice. The internalization wizard in IDEAS was used to determine the interaction of the GFP-positive bacteria with phagocytes (not associated, surface bound, or internalized). (A) Percentages of macrophages interacting with GFP-positive *S. aureus*. Shown are means and SEM. **, $P < 0.01$; *, $P < 0.05$; ns, not significant (Kruskal-Wallis test with Dunn's multiple-comparison test). (B) Representative micrographs of macrophages in association with GFP-expressing *S. aureus* (MOI, 5) analyzed by imaging flow cytometry. *S. aureus* Newman was incubated with 25% sera from WT and $C3^{-/-}$ mice in PBS at 37°C for 30 min and then diluted to the expected concentration and injected i.v. (4×10^6 CFU/mouse) into $C3^{-/-}$ mice. (C and D) The severity (C) and frequency (D) of clinical arthritis were observed for 10 days postinfection. (E) Changes in body weight registered as percentages of the initial body weight. (F) Kidney abscess scores 10 days after infection. Shown are means and SEM.

DISCUSSION

In this study, we demonstrated that C3 deficiency significantly increased both the frequency and severity of *S. aureus* hematogenous septic arthritis in mice. C3-deficient mice had impaired ability to clear *S. aureus* and showed more pronounced weight loss. C3aR deficiency had no impact on the development of hematogenous septic arthritis, suggesting that the observed effects of C3 deficiency in hematogenous septic arthritis are largely due to impaired opsonization mediated by C3b rather than C3a-induced proinflammatory responses. In further support of this notion, serum from $C3^{-/-}$ mice failed to opsonize the bacteria, and preincubation of *S. aureus* with WT serum prior to hematogenous injection was associated with a trend toward milder arthritis in $C3^{-/-}$ mice. Taken together, these results show that C3-mediated

opsonization plays a critical role in protecting the host against *S. aureus* septic arthritis.

As the great majority of septic arthritis in humans is spread hematogenously, our hematogenous model of septic arthritis induced by intravenous inoculation of *S. aureus* closely resembles the human disease (21). We propose that the development of hematogenous septic arthritis can be divided into two stages—early and late. During the early stage, *S. aureus* needs to adapt to the host environment, to survive the bactericidal components and phagocyte attacks in the blood, to disseminate to synovial tissue, and finally to reach the joint cavity. In the joint cavity (late stage), *S. aureus* proliferates and releases a vast arsenal of components that arouse a host response and cause joint damage. As the intra-articular route of bacterial inoculation bypasses the early stage of dis-




FIG 5 C3aR deficiency did not affect the course of hematogenous staphylococcal arthritis. C3aR^{-/-} and WT mice were intravenously inoculated with *S. aureus* strain Newman (4×10^6 CFU/mouse) and killed on day 10. (A and B) The severity (A) and frequency (B) of clinical arthritis were observed for 10 days postinfection. (C) Changes in body weight registered as percentages of the initial body weight. (D) Kidney abscess scores 10 days after infection. Shown are means and SEM. *, $P < 0.05$; ns, not significant. Mann-Whitney *U* test or Fisher's exact test.

ease pathogenesis, our local *S. aureus* arthritis model can be considered a means to study the later stage of immune responses *in situ*. Our finding that C3 deficiency led to significantly increased arthritis severity in a hematogenous *S. aureus* arthritis model but not in a local *S. aureus* arthritis model strongly suggests that the deleterious effect of C3 deficiency in hematogenous septic arthritis was due to the critical role of C3 in the early stage of the disease, i.e., before the bacteria reach the joint cavity.

It takes 2 to 3 days for the signs of clinical septic arthritis to become evident after intravenous inoculation of *S. aureus* (22, 28), indicating that the early stage of the disease is relatively short. During this short time, neutrophils are the predominant phagocytes responsible for the elimination of invading *S. aureus* by phagocytosis. Septic arthritis in neutrophil-depleted mice and in C3-deficient mice shows very similar disease patterns, e.g., a higher bacterial load in the kidneys, more severe arthritis, and greater body weight loss (4), indicating a strong connection between neutrophils and C3 in hematogenous septic arthritis.

In septic arthritis, the only initial cause of clinical synovitis and bone erosions is the invading *S. aureus* in affected joints. Significantly higher frequency of clinical synovitis and CT-verified bone damage in C3-deficient mice strongly suggest that the absence of C3 leads to impaired bacterial clearance and a larger number of *S. aureus* bacteria reaching more joints. C3a liberated in the course of complement activation has been shown to exhibit antimicrobial activity (29). A direct killing effect of C3a on *S. aureus* was also observed (30). Direct antimicrobial activity of C3a at the infection

site might contribute to host innate immunity, controlling invading pathogens. C3b, another product of C3 activation, is recognized by complement receptors expressed on the phagocytes. This recognition leads to subsequent internalization of the opsonized bacteria by phagocytic cells. The C3b opsonin can be generated by the classical complement pathway, typically initiated by binding of antigen-specific antibody that attracts complement C1q and the consequent formation of the C3 convertase C4b2a. The same C3 convertase is formed in response to carbohydrate structures present on microbial surfaces and is initiated through multimolecular fluid phase complexes composed of a carbohydrate recognition subcomponent (mannose-binding lectin or ficolin L, H, or M) and the lectin pathway serine protease, mannan-binding lectin-associated serine protease 2. In contrast, the alternative pathway of complement activation and the generation of the alternative-pathway C3 convertase (C3bBb) is the result of direct binding of C3b or C3(H₂O) to the target surface. All three activation pathways have been shown to contribute to the opsonization of *S. aureus* (31–34). Our data support the conclusion that complement activation by the classical and/or lectin pathway is of critical importance for the clearance of *S. aureus* from the systemic circulation, whereas the alternative pathway plays only a secondary role in the opsonization of *S. aureus* used in our study.

In contrast to C3 deficiency, *fB*^{-/-} mice maintained normal production of CCL5, a potent chemokine that recruits neutrophils to the infected tissue via C-C chemokine receptor type 1. Further, *fB* deficiency had no effect on phagocytosis and was not associated

with increased susceptibility to hematogenous septic arthritis. These data further strengthen our conclusion that the alternative pathway of complement activation is not essential for host resistance to *S. aureus* and the pathogenesis of septic arthritis.

The production of specific antibodies against *S. aureus* could be impaired in C3-deficient mice, since the complement system is known to maintain the proper function of B cells and mice deficient in complement receptors and C3 have impaired antibody responses to T-cell-dependent antigen (35, 36). Given the short time between inoculation and symptoms of arthritis in our model, our *in vivo* findings and the reduced *in vitro* phagocytosis of bacteria incubated with C3-deficient but not fB-deficient serum could be at least partly due to lower levels of specific antibodies against *S. aureus* present *a priori* in the blood of mice and not the specific antibody response triggered by the inoculation as such. We have previously shown that both $C3^{-/-}$ and $fB^{-/-}$ mice respond by low specific antibody production to single immunization with collagen II but that this impaired antibody response is overcome by repeated immunizations (37). Although we have not been able to quantify the specific antibody levels in our mice, it is conceivable that all the mice had had previous and repeated exposure to *S. aureus*. Hence, the differences between the $C3^{-/-}$ and the $fB^{-/-}$ and WT mice in clinical arthritis and the opsonization capacity of $C3^{-/-}$ versus $fB^{-/-}$ and WT sera are conceivably due to the absence of C3 and not due to lower levels of antibodies specific for *S. aureus*.

As C3a was shown to activate divergent signaling pathways that induce chemokine production (38, 39), it is not surprising that serum MCP-1 and CCL5 levels were significantly lower in C3-deficient mice. Our findings of lower serum IL-12 (a proinflammatory Th1 cytokine) and IL-10 (an anti-inflammatory Th2 cytokine) levels in $C3^{-/-}$ than in WT mice also point to the impaired immune responses to *S. aureus* infection in the absence of C3. RANKL plays a role in bone metabolism and bone resorption (40). However, as RANKL is highly expressed by many cell types, including activated T cells (41), and T-cell responses are reduced in C3-deficient mice, it is not surprising that serum RANKL levels were not significantly elevated in C3-deficient mice despite significantly more severe bone destruction. Our data also suggest that systemic RANKL levels may not be a good indicator of bone destructions in septic arthritis.

It has been suggested that the severity of *S. aureus* septic arthritis is not exclusively linked to the number of bacteria present in the joint but is also determined by other factors, including proinflammatory cytokines and the extent of leukocyte infiltration in the synovium (22). $CD4^{+}$ T cells are known to be pathogenic in the course of *S. aureus* arthritis in mice, and pretreatment with anti- $CD4$ antibodies attenuated the severity of *S. aureus* septic arthritis in mice (6, 7). The complement system is known to regulate T-cell responses (42). In C3-deficient mice, the priming of both $CD4^{+}$ and $CD8^{+}$ T cells was impaired in an influenza virus model (43). Intracellular C3 convertase-independent C3a generation and C3aR activation contribute to homeostatic mTOR activity and T-cell survival, and increased intracellular C3 activation underlies T effector dysregulation in arthritis (44). Direct signaling by C3a and C5a through their receptors on lung dendritic cells is required for their efficient trafficking to the draining lymph nodes, which is a crucial step for the initiation of T-cell responses (45). Upon T-cell activation, both C3aR and C5aR expression is induced on T cells, and these cells respond to C3a and C5a with directed che-

motactic migration (46, 47). Our findings that C3aR deficiency did not alter arthritis severity in mice with hematogenous septic arthritis, however, strongly support the conclusion that, compared to the opsonization effect of C3b, the involvement of C3a/C3aR-mediated proinflammatory processes plays only a minor role in the development of septic arthritis.

Due to widespread and excessive consumption of antibiotics, antibiotic resistance in *S. aureus* has expanded worldwide and continues to expand at an accelerating rate. There is an urgent need for novel treatment strategies, including improvement of innate immune defense to clear human pathogens, as well as the discovery of new antibiotics. Our data demonstrate the essential protective role of C3-mediated opsonization in host defense against *S. aureus* hematogenous septic arthritis and raise the possibility of enhancing C3 function for new antistaphylococcal treatments. *S. aureus* uses a range of strategies to escape complement attack, e.g., by producing complement-inhibitory proteins that act on C3 or C3 convertases, such as extracellular fibrinogen-binding protein (48, 49) and staphylococcal complement inhibitor (SCIN) (50). Neutralization of these key staphylococcal virulence mechanism by vaccination or small molecules blocking the interaction of inhibitory proteins with C3, therefore, represents an attractive therapeutic approach for *S. aureus* septic arthritis.

ACKNOWLEDGMENTS

We do not have any commercial associations that might pose a conflict of interest.

This work was supported by the Swedish Medical Research Council (grants D0275001 and D0275002 to T. Jin), the Swedish Medical Society (SLS-496741 and SLS-402871 to T. Jin), the Stiftelsen Clas Groschinskys Minnesfond (grants M1566 and M14099 to T. Jin), the Royal Society of Arts and Sciences in Gothenburg (grants to T. Jin and M. Na), the Wilhelm and Martina Lundgren Foundation (grants to T. Jin, M. Na, and A. Jarneborn), the Scandinavian Society for Antimicrobial Chemotherapy Foundation (grant SLS-501701 to T. Jin), Rune och Ulla Amlövs Stiftelse för Neurologisk och Reumatologisk Forskning (grant 2015-00056 to T. Jin), and Adlerbertska Forskningsstiftelsen (grants to T. Jin and M. Na).

FUNDING INFORMATION

Swedish Medical Society provided funding to Tao Jin under grant numbers SLS-496741 and SLS-402871. Scandinavian Society for Antimicrobial Chemotherapy Foundation provided funding to Tao Jin under grant number SLS-501701. Adlerbertska Stiftelserna (Adlerbertska Foundations) provided funding to Tao Jin. Vetenskapsrådet (VR) provided funding to Tao Jin under grant numbers D0275001 and D0275002. Stiftelserna Wilhelm och Martina Lundgrens (Wilhelm and Martina Lundgren Foundation) provided funding to Tao Jin. Stiftelsen Clas Groschinskys Minnesfond (Clas Groschinski Memorial Foundation) provided funding to Tao Jin under grant numbers M1566 and M14099. Rune och Ulla Amlövs Stiftelse för Neurologisk och Reumatologisk Forskning (Rune och Ulla Amlövs Stiftelse) provided funding to Tao Jin.

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

REFERENCES

1. Goldenberg DL. 1998. Septic arthritis. *Lancet* 351:197–202. [http://dx.doi.org/10.1016/S0140-6736\(97\)09522-6](http://dx.doi.org/10.1016/S0140-6736(97)09522-6).
2. Garcia-Arias M, Balsa A, Mola EM. 2011. Septic arthritis. *Best Pract Res Clin Rheumatol* 25:407–421. <http://dx.doi.org/10.1016/j.berh.2011.02.001>.
3. Gould IM, David MZ, Esposito S, Garau J, Lina G, Mazzei T, Peters G. 2012. New insights into methicillin-resistant *Staphylococcus aureus*

- (MRSA) pathogenesis, treatment and resistance. *Int J Antimicrob Agents* 39:96–104. <http://dx.doi.org/10.1016/j.ijantimicag.2011.09.028>.
4. Verdrengh M, Tarkowski A. 1997. Role of neutrophils in experimental septicemia and septic arthritis induced by *Staphylococcus aureus*. *Infect Immun* 65:2517–2521.
 5. Nilsson N, Bremell T, Tarkowski A, Carlsten H. 1999. Protective role of NK1.1+ cells in experimental *Staphylococcus aureus* arthritis. *Clin Exp Immunol* 117:63–69. <http://dx.doi.org/10.1046/j.1365-2249.1999.00922.x>.
 6. Abdelnour A, Bremell T, Holmdahl R, Tarkowski A. 1994. Role of T lymphocytes in experimental *Staphylococcus aureus* arthritis. *Scand J Immunol* 39:403–408. <http://dx.doi.org/10.1111/j.1365-3083.1994.tb03392.x>.
 7. Abdelnour A, Bremell T, Holmdahl R, Tarkowski A. 1994. Clonal expansion of T lymphocytes causes arthritis and mortality in mice infected with toxic shock syndrome toxin-1-producing staphylococci. *Eur J Immunol* 24:1161–1166. <http://dx.doi.org/10.1002/eji.1830240523>.
 8. Walport MJ. 2001. Complement. First of two parts. *N Engl J Med* 344:1058–1066. <http://dx.doi.org/10.1056/NEJM200104053441406>.
 9. Carroll MC. 2004. The complement system in regulation of adaptive immunity. *Nat Immunol* 5:981–986. <http://dx.doi.org/10.1038/nri1113>.
 10. Joiner KA, Brown EJ, Frank MM. 1984. Complement and bacteria: chemistry and biology in host defense. *Annu Rev Immunol* 2:461–491. <http://dx.doi.org/10.1146/annurev.iy.02.040184.002333>.
 11. Berends ET, Dekkers JF, Nijland R, Kuipers A, Soppe JA, van Strijp JA, Rooijackers SH. 2013. Distinct localization of the complement C5b-9 complex on Gram-positive bacteria. *Cell Microbiol* 15:1955–1968. <http://dx.doi.org/10.1111/cmi.12170>.
 12. von Kockritz-Blickwede M, Konrad S, Foster S, Gessner JE, Medina E. 2010. Protective role of complement C5a in an experimental model of *Staphylococcus aureus* bacteremia. *J Innate Immun* 2:87–92. <http://dx.doi.org/10.1159/000247157>.
 13. Cunnion KM, Benjamin DK, Jr, Hester CG, Frank MM. 2004. Role of complement receptors 1 and 2 (CD35 and CD21), C3, C4, and C5 in survival by mice of *Staphylococcus aureus* bacteremia. *J Lab Clin Med* 143:358–365. <http://dx.doi.org/10.1016/j.lab.2004.03.005>.
 14. Takahashi K, Shi L, Gowda LD, Ezekowitz RA. 2005. Relative roles of complement factor 3 and mannose-binding lectin in host defense against infection. *Infect Immun* 73:8188–8193. <http://dx.doi.org/10.1128/IAI.73.12.8188-8193.2005>.
 15. Shi L, Takahashi K, Dundee J, Shahroor-Karni S, Thiel S, Jensenius JC, Gad F, Hamblin MR, Sastry KN, Ezekowitz RA. 2004. Mannose-binding lectin-deficient mice are susceptible to infection with *Staphylococcus aureus*. *J Exp Med* 199:1379–1390. <http://dx.doi.org/10.1084/jem.20032207>.
 16. Sakiniene E, Bremell T, Tarkowski A. 1999. Complement depletion aggravates *Staphylococcus aureus* septicemia and septic arthritis. *Clin Exp Immunol* 115:95–102. <http://dx.doi.org/10.1046/j.1365-2249.1999.00771.x>.
 17. Pekna M, Hietala MA, Rosklint T, Betsholtz C, Pekny M. 1998. Targeted disruption of the murine gene coding for the third complement component (C3). *Scand J Immunol* 47:25–29. <http://dx.doi.org/10.1046/j.1365-3083.1998.00274.x>.
 18. Kildsgaard J, Hollmann TJ, Matthews KW, Bian K, Murad F, Wetsel RA. 2000. Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. *J Immunol* 165:5406–5409. <http://dx.doi.org/10.4049/jimmunol.165.10.5406>.
 19. Pekna M, Hietala MA, Landin A, Nilsson AK, Lagerberg C, Betsholtz C, Pekny M. 1998. Mice deficient for the complement factor B develop and reproduce normally. *Scand J Immunol* 47:375–380. <http://dx.doi.org/10.1046/j.1365-3083.1998.00313.x>.
 20. Kwiecinski J, Jacobsson G, Karlsson M, Zhu X, Wang W, Bremell T, Josefsson E, Jin T. 2013. Staphylokinase promotes the establishment of *Staphylococcus aureus* skin infections while decreasing disease severity. *J Infect Dis* 208:990–999. <http://dx.doi.org/10.1093/infdis/jit288>.
 21. Tarkowski A, Collins LV, Gjertsson I, Hultgren OH, Jonsson IM, Sakiniene E, Verdrengh M. 2001. Model systems: modeling human staphylococcal arthritis and sepsis in the mouse. *Trends Microbiol* 9:321–326. [http://dx.doi.org/10.1016/S0966-842X\(01\)02078-9](http://dx.doi.org/10.1016/S0966-842X(01)02078-9).
 22. Ali A, Welin A, Schwarze JC, Svensson MN, Na M, Jarneborn A, Magnusson M, Mohammad M, Kwiecinski J, Josefsson E, Bylund J, Pullerits R, Jin T. 2015. CTLA4 immunoglobulin but not anti-tumor necrosis factor therapy promotes staphylococcal septic arthritis in mice. *J Infect Dis* 212:1308–1316. <http://dx.doi.org/10.1093/infdis/jiv212>.
 23. Ali A, Na M, Svensson MN, Magnusson M, Welin A, Schwarze JC, Mohammad M, Josefsson E, Pullerits R, Jin T. 2015. IL-1 Receptor antagonist treatment aggravates staphylococcal septic arthritis and sepsis in mice. *PLoS One* 10:e0131645. <http://dx.doi.org/10.1371/journal.pone.0131645>.
 24. Fei Y, Wang W, Kwiecinski J, Josefsson E, Pullerits R, Jonsson IM, Magnusson M, Jin T. 2011. The combination of a tumor necrosis factor inhibitor and antibiotic alleviates staphylococcal arthritis and sepsis in mice. *J Infect Dis* 204:348–357. <http://dx.doi.org/10.1093/infdis/jir266>.
 25. Ali A, Zhu X, Kwiecinski J, Gjertsson I, Lindholm C, Iwakura Y, Wang X, Lycke N, Josefsson E, Pullerits R, Jin T. 2015. Antibiotic-killed *Staphylococcus aureus* induces destructive arthritis in mice. *Arthritis Rheumatol* 67:107–116. <http://dx.doi.org/10.1002/art.38902>.
 26. Thaddeus L, Bjorkman L, Christenson K, Alsterholm M, Movitz C, Thoren FB, Karlsson A, Welin A, Bylund J. 2013. A simple skin blister technique for the study of in vivo transmigrating of human leukocytes. *J Immunol Methods* 393:8–17. <http://dx.doi.org/10.1016/j.jim.2013.03.013>.
 27. Zipfel PF, Skerka C. 2009. Complement regulators and inhibitory proteins. *Nat Rev Immunol* 9:729–740. <http://dx.doi.org/10.1038/nri2620>.
 28. Bremell T, Lange S, Yacoub A, Ryden C, Tarkowski A. 1991. Experimental *Staphylococcus aureus* arthritis in mice. *Infect Immun* 59:2615–2623.
 29. Nordahl EA, Rydengard V, Nyberg P, Nitsche DP, Morgelin M, Malmsten M, Bjorck L, Schmidtchen A. 2004. Activation of the complement system generates antibacterial peptides. *Proc Natl Acad Sci U S A* 101:16879–16884. <http://dx.doi.org/10.1073/pnas.0406678101>.
 30. Koch TK, Reuter M, Barthel D, Bohm S, van den Elsen J, Kraiczky P, Zipfel PF, Skerka C. 2012. *Staphylococcus aureus* proteins Sbi and Efb recruit human plasmin to degrade complement C3 and C3b. *PLoS One* 7:e47638. <http://dx.doi.org/10.1371/journal.pone.0047638>.
 31. Forsgren A, Quie PG. 1974. Influence of the alternate complement pathway in opsonization of several bacterial species. *Infect Immun* 10:402–404.
 32. Spika JS, Verbrugh HA, Verhoef J. 1981. Protein A effect on alternative pathway complement activation and opsonization of *Staphylococcus aureus*. *Infect Immun* 34:455–460.
 33. Verbrugh HA, Peterson PK, Nguyen BY, Sisson SP, Kim Y. 1982. Opsonization of encapsulated *Staphylococcus aureus*: the role of specific antibody and complement. *J Immunol* 129:1681–1687.
 34. Lynch NJ, Roscher S, Hartung T, Morath S, Matsushita M, Maennel DN, Kuraya M, Fujita T, Schwaible WJ. 2004. L-ficolin specifically binds to lipoteichoic acid, a cell wall constituent of Gram-positive bacteria, and activates the lectin pathway of complement. *J Immunol* 172:1198–1202. <http://dx.doi.org/10.4049/jimmunol.172.2.1198>.
 35. Fischer MB, Ma M, Goerg S, Zhou X, Xia J, Finco O, Han S, Kelsoe G, Howard RG, Rothstein TL, Kremmer E, Rosen FS, Carroll MC. 1996. Regulation of the B cell response to T-dependent antigens by classical pathway complement. *J Immunol* 157:549–556.
 36. Molina H, Holers VM, Li B, Fung Y, Mariathan S, Goellner J, Strauss-Schoenberger J, Karr RW, Chaplin DD. 1996. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. *Proc Natl Acad Sci U S A* 93:3357–3361. <http://dx.doi.org/10.1073/pnas.93.8.3357>.
 37. Hietala MA, Jonsson IM, Tarkowski A, Kleinau S, Pekna M. 2002. Complement deficiency ameliorates collagen-induced arthritis in mice. *J Immunol* 169:454–459. <http://dx.doi.org/10.4049/jimmunol.169.1.454>.
 38. Sewell DL, Nacewicz B, Liu F, Macvilay S, Erdei A, Lambris JD, Sandor M, Fabry Z. 2004. Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. *J Neuroimmunol* 155:55–63. <http://dx.doi.org/10.1016/j.jneuroim.2004.06.003>.
 39. Venkatesha RT, Berla Thangam E, Zaidi AK, Ali H. 2005. Distinct regulation of C3a-induced MCP-1/CCL2 and RANTES/CCL5 production in human mast cells by extracellular signal regulated kinase and PI3 kinase. *Mol Immunol* 42:581–587. <http://dx.doi.org/10.1016/j.molimm.2004.09.009>.
 40. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. *Proc Natl Acad Sci U S A* 95:3597–3602. <http://dx.doi.org/10.1073/pnas.95.7.3597>.
 41. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C,

- Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM. 1999. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. *Nature* 402:304–309. <http://dx.doi.org/10.1038/46303>.
42. Kemper C, Atkinson JP. 2007. T-cell regulation: with complements from innate immunity. *Nat Rev Immunol* 7:9–18. <http://dx.doi.org/10.1038/nri1994>.
 43. Kopf M, Abel B, Gallimore A, Carroll M, Bachmann MF. 2002. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. *Nat Med* 8:373–378. <http://dx.doi.org/10.1038/nm0402-373>.
 44. Liszewski MK, Kolev M, Le Fric G, Leung M, Bertram PG, Fara AF, Subias M, Pickering MC, Drouet C, Meri S, Arstila TP, Pekkarinen PT, Ma M, Cope A, Reinheckel T, Rodriguez de Cordoba S, Afzali B, Atkinson JP, Kemper C. 2013. Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. *Immunity* 39:1143–1157. <http://dx.doi.org/10.1016/j.immuni.2013.10.018>.
 45. Kandasamy M, Ying PC, Ho AW, Sumatoh HR, Schlitzer A, Hughes TR, Kemeny DM, Morgan BP, Ginhoux F, Sivasankar B. 2013. Complement mediated signaling on pulmonary CD103(+) dendritic cells is critical for their migratory function in response to influenza infection. *PLoS Pathog* 9:e1003115. <http://dx.doi.org/10.1371/journal.ppat.1003115>.
 46. Werfel T, Kirchhoff K, Wittmann M, Begemann G, Kapp A, Heidenreich F, Gotze O, Zirner J. 2000. Activated human T lymphocytes express a functional C3a receptor. *J Immunol* 165:6599–6605. <http://dx.doi.org/10.4049/jimmunol.165.11.6599>.
 47. Nataf S, Davoust N, Ames RS, Barnum SR. 1999. Human T cells express the C5a receptor and are chemoattracted to C5a. *J Immunol* 162:4018–4023.
 48. Hammel M, Sfyroera G, Ricklin D, Magotti P, Lambris JD, Geisbrecht BV. 2007. A structural basis for complement inhibition by *Staphylococcus aureus*. *Nat Immunol* 8:430–437. <http://dx.doi.org/10.1038/ni1450>.
 49. Palma M, Nozohoor S, Schennings T, Heimdahl A, Flock JI. 1996. Lack of the extracellular 19-kilodalton fibrinogen-binding protein from *Staphylococcus aureus* decreases virulence in experimental wound infection. *Infect Immun* 64:5284–5289.
 50. Rooijackers SH, Ruyken M, Roos A, Daha MR, Presanis JS, Sim RB, van Wamel WJ, van Kessel KP, van Strijp JA. 2005. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. *Nat Immunol* 6:920–927. <http://dx.doi.org/10.1038/ni1235>.